Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
Intervalo de año de publicación
1.
BMC Vet Res ; 18(1): 72, 2022 Feb 18.
Artículo en Inglés | MEDLINE | ID: mdl-35180858

RESUMEN

BACKGROUND: Bacterial ghosts are the evacuated bacterial cellular membranes from most of the genetic and protein contents which preserved their surface characters. Recently, bacterial ghosts exploited for different biomedical applications, for instance, vaccination. The purpose of this study is to measure the immunogenic protective response of bacterial ghosts of Salmonella Typhimurium in animals and to allow future testing this response in humans. The immunologic response was qualitatively, quantitatively, and functionally measured. We have measured the humoral and cellular immune responses, such as immunoglobulins elevation (IgG), increased granulocytes, serum antibacterial activity, clearance of virulence in feces and liver, and the survival rate. RESULTS: The bacterial ghosts' vaccine was able to protect 100% of subcutaneously vaccinated rats and 75% of adjuvant subcutaneously vaccinated rats. The lowest survival rate was in the orally vaccinated group (25%). The maximum level of serum IgG titers, as well as serum and feces bactericidal activity (100% eradication), was exhibited in the subcutaneously vaccinated group with adjuvant vaccines followed by the subcutaneously vaccinated one. Additionally, the highest granulocytes' number was observed in the adjuvant vaccine subcutaneously immunized group. The bacterial load in liver homogenate was eliminated in the subcutaneously vaccinated rats after the virulence challenge. CONCLUSIONS: The bacterial ghosts of Salmonella enterica serovar Typhimurium that prepared by Tween 80 Protocol showed an effective vaccine candidate that protected animals, eliminated the virulence in feces and liver. These findings show that chemically induced bacterial ghosts of Salmonella Typhimurium can be a promising vaccine.


Asunto(s)
Enfermedades de los Roedores , Salmonelosis Animal , Vacunas contra la Salmonella , Animales , Anticuerpos Antibacterianos , Formación de Anticuerpos , Vacunas Bacterianas , Ratas , Salmonelosis Animal/prevención & control , Salmonella typhimurium , Vacunas Atenuadas
2.
Saudi Pharm J ; 28(10): 1253-1262, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-33132719

RESUMEN

Cell- based targeted delivery is recently gain attention as a promising platform for delivery of anticancer drug in selective and efficient manner. As a new biotechnology platform, bacterial ghosts (BGs) have novel biomedical application as targeted drug delivery system (TDDS). In the current work, Salmonellas' BGs was utilized for the first time as hepatocellular cancer (HCC) in-vitro targeted delivery system. Successful BGs loading and accurate analysis of doxorubicin (DOX) were necessary steps for testing the applicability of DOX loaded BGs in targeting the liver cancer cells. Loading capacity was maximized to reach 27.5 µg/mg (27.5% encapsulation efficiency), by incubation of 10 mg BGs with 1 mg DOX at pH 9 in constant temperature (25 °C) for 10 min. In-vitro release study of DOX loaded BGs showed a sustained release (182 h) obeying Higuchi sustained kinetic release model. The death rate (tested by MTT assay) of HepG2 reached to 64.5% by using of 4 µg/ml, while it was about 51% using the same concentration of the free DOX (P value < 0.0001 One-way ANOVA analysis). The proliferative inhibitory concentration (IC50) of the DOX combined formula was 1.328 µg/ml that was about one third of the IC50 of the free DOX (3.374 µg/ml). Apoptosis analysis (tested by flow-cytometry) showed more accumulation in early apoptosis (8.3%) and late apoptosis/necrosis (91%) by applying 1 µg/ml BGs combined DOX, while 1 µg/ml free DOX showed 33.4% of cells in early apoptosis and 39.3% in late apoptosis/necrosis, (P value˃ 0.05: one-way ANOVA). In conclusion, DOX loaded Salmonellas' BGs are successfully prepared and tested in vivo with promising potential as hepatocellular cancer (HCC) targeted delivery system.

3.
Saudi Pharm J ; 26(2): 232-237, 2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-30166921

RESUMEN

Bacterial ghosts (BGs) can be prepared by both genetic and chemical means. Genetic method include using lysis gene E. Chemical method include incubation with numerous agents for a short time at their minimum inhibitory or minimum growth concentrations (MIC or MGC). The aim of this study is to prepare the BGs with a new protocol via exposing the bacterial cells to tween 80 for an extended period of time followed by sudden reduction of the surrounding pH. Salmonella enterica serovar typhimurium ATCC 13311 was used for this purpose. The cells were incubated in 7% v/v tween 80 solution in Muller-Hinton broth for 24 h at 37 °C then pH was decreased to 3.6 by adding lactic acid for one hour. The bacterial pellets were separated by high speed centrifugation, and then washed three times by half normal saline solution. High quality BGs were visualized by scanning electron microscopy (SEM) revealing punctured cells with intact outer shells and at least one intramembranous tunnel. The absence of vital cells was confirmed by subculturing. The release of respective amounts of proteins and DNA is another evidence of ghost's production. In addition, the integrity of cells was proved by visualization of Gram-stained cells using light microscopy. In conclusion, this new protocol is simple, economic and feasible for BGs preparation.

4.
BMC Res Notes ; 5: 125, 2012 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-22381042

RESUMEN

BACKGROUND: Hepatitis B is a liver disease primarily caused by hepatitis B virus (HBV) infection. It is distributed worldwide and associated with high mortality and morbidity rates. HBV infections can be avoided by the administration of the currently available vaccine and can be easily diagnosed through commercially available kits. Both the vaccine and the diagnostic kits depend on using the hepatitis B surface antigen (HBsAg) as an antigen. Developing countries such as, Egypt, suffer from the widespread of HBV infections and the limited resources to provide adequate supplies of either the vaccine or the diagnostic kits. Therefore the need for an easy, rapid, low cost method to produce HBsAg is urgently needed within this setting. FINDINGS: To achieve this goal, the gene encoding the HBsAg(S) protein was cloned and expressed as a fusion protein with a GST tag in Escherichia coli. The recombinant protein was successfully expressed and purified in both good quality and quantity. CONCLUSIONS: The simplified and the relatively low cost of the used protocol make this an attractive alternative to protocols currently used for the purification of HBsAg(S). The exploiting of this achievement for new diagnostics can be directed for application in the developing countries where they are extremely needed.


Asunto(s)
Escherichia coli/genética , Antígenos de Superficie de la Hepatitis B/genética , Antígenos de Superficie de la Hepatitis B/aislamiento & purificación , Virus de la Hepatitis B/genética , Electroforesis en Gel de Poliacrilamida , Expresión Génica , Glutatión Transferasa/genética , Glutatión Transferasa/metabolismo , Antígenos de Superficie de la Hepatitis B/metabolismo , Virus de la Hepatitis B/metabolismo , Reacción en Cadena de la Polimerasa , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/aislamiento & purificación , Proteínas Recombinantes de Fusión/metabolismo , Temperatura , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA